According to a recent LinkedIn post from Touchlight, the company plans to attend the ASGCT 2026 meeting in Boston from May 11–15, where it will engage with partners and developers at booth 1334. The post highlights Touchlight’s focus on cell‑free DNA technologies, including its mbDNA and Custom Circles offerings, positioned as alternatives to plasmid DNA.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post suggests it aims to showcase how these platforms may help gene and cell therapy developers accelerate development timelines and address manufacturing constraints. For investors, the planned presence at a major industry conference could indicate continued commercial outreach and potential for business development activity in DNA manufacturing for advanced therapies.
The emphasis on overcoming limitations of plasmid DNA points to Touchlight’s effort to differentiate its platform in a competitive nucleic acid production landscape. If interest from therapy developers translates into new collaborations or supply agreements, the visibility at ASGCT 2026 could support revenue growth prospects and strengthen the company’s position in the gene and cell therapy supply chain.